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 Background 
 Several recent publications have focused on the appli-
cation of the WHO classification of GEP-NETs and 
proved its effectiveness, supporting the concept that the 
various GEP-NET types also differ in their clinical be-
havior. Because of this biological diversity, the treatment 
of GEP-NETs is becoming more and more type-specific 
 [4–11] .
 Recent data from the German NET registry have re-
vealed that approximately one third of the cases report-
ed between 2000 and 2006 lack a documented histopath-
ological diagnosis, and in even more cases the tentative 
diagnosis of a NET was not confirmed by using neuro-
endocrine markers, nor was the proliferation deter-
mined by using Ki67/MIB1 [Plöckinger, unpubl. data]. 
 Introduction 
 In order to assure an optimal treatment of gastroen-
teropancreatic neuroendocrine tumors (GEP-NETs), a 
standardized diagnostic procedure is required. This need 
prompted the European Neuroendocrine Tumor Society 
(ENETS) to organize a third Consensus Conference, 
which was held in La Palma (Mallorca) in 2007. One re-
sult was a proposal for a standardized approach to the 
morphological diagnosis of GEP-NETs, whose needs and 
options were designed, discussed and consensually ap-
proved. In addition, a working formulation for a diagnos-
tic and prognostic stratification was proposed based on 
histological typing, differentiation, grading and TNM 
staging  [1–3] .
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This emphasizes the need for a standardized morpho-
logical procedure that would result in a diagnosis suffi-
cient to meet all criteria necessary for exact recognition 
and optimal treatment. During the recent Standards of 
Care Conference of ENETS held in La Palma (Mallorca, 
Spain) from November 29 to December 1, 2007, a proto-
col for the morphological diagnosis of GEP-NETs was 
discussed and approved. Here we report on the recom-
mended diagnostic procedure, focusing on the needs 
and options.
 Needs and Options 
 Tissue from GEP-NETs for use in diagnostic proce-
dures is obtained either by biopsy from a primary tumor 
or a metastasis (i.e. liver, lymph node) or by surgical re-
moval of tumor tissue. The biopsy specimen is usually 
formalin-fixed when it is received by the pathology labo-
ratory, while the surgical resection specimen may arrive 
as fresh tissue that can be frozen and stored before the 
remaining tissue is fixed in formalin. The biopsy speci-
men is immediately processed for histopathological as-
sessment, whereas the resection specimen requires a 
thorough and detailed gross examination and descrip-
tion of the lesions observed, before tissue blocks are sam-
pled and obtained for histology. Gross examination and 
description are necessary in order to provide the data and 
criteria on which the TNM classification is based. In par-
ticular, information has to be provided on the resection 
margins, the tumor location, the relationship of the tu-
mor to other organs, the tumor’s size, invasiveness and 
composition and the presence of regional metastases.
 Diagnostic Standards 
 Table 1 depicts the standard procedure for the diag-
nosis of NET in a biopsy specimen. It shows the ‘musts 
and options’ that follow the recognition of a tumor with 
endocrine features on an HE-stained section from a bi-
opsy specimen. Crucial for the diagnosis is the demon-
stration of the neuroendocrine markers synaptophysin 
and chromogranin A in the tumor cells  [12, 13] . Synap-
tophysin, which is an integral membrane protein of small 
clear vesicles (diameter 40–80 nm) occurring in all nor-
mal and neoplastic neuroendocrine cells, is diffusely ex-
pressed in the cytoplasm of all cells of a NET. Chromo-
granin A, which is a protein located in the matrix of large 
secretory granules ( 1 80 nm) is, in contrast to synapto-
physin, inhomogeneously expressed in the cytoplasm of 
the tumor cell or can even be lacking, since its expression 
depends on the number of neurosecretory granules pres-
ent in the cells and on the cell type. In small cell neuro-
endocrine carcinoma of the lung (because of the small 
number of secretory granules per cell) and in rectal NETs 
(because of the specific cell type of these neoplasms), 
chromogranin A is usually lacking, but in most well-dif-
ferentiated neuroendocrine neoplasms with abundant 
secretory granules, chromogranin A is intensely ex-
pressed. There is no need for a semiquantitative evalua-
tion of synaptophysin and chromogranin A stainings, 
since such information is currently of no use for clinical 
purposes.
 The application of neuron-specific enolase (NSE) and 
other markers such as CD56 (i.e. NCAM) and PGP9.5 for 
the recognition of GEP-NETs is discouraged, due to the 
frequent unspecificity of the available antibodies (in the 
case of NSE) or the unspecificity of the marker itself (in the 
case of CD56)  [13] . For visualization of the suggested mark-
ers, staining techniques and antibodies that have been ap-
proved in quality assurance procedures should be used.
 Once the neuroendocrine nature of the tumor has 
been established, its differentiation and proliferative ac-
tivity have to be determined. As to the differentiation, 
well- and poorly-differentiated NETs have to be distin-
guished according to the WHO classification  [14] . The 
proliferative activity can be determined by counting the 
mitoses per high-power field and/or – more easily – by 
Table 1. Musts and options for assessing a biopsy specimen con-
taining a tumor with features of a well- or poorly-differentiated 
GEP-NET
Must
Immunostaining for neuroendocrine markers
– Synaptophysin and chromogranin
Immunostaining for proliferation marker
– Ki67/MIB1
Optional
Immunostaining for hormones such as insulin, gastrin,
serotonin and others
Because of hormonal symptoms, liver metastases of
an unknown primary or follow-up of a tumor with a
hormonal syndrome
Immunostaining for somatostatin receptor (i.e. SSTR2)
Because of diagnostic/therapeutical tumor management
Immunostaining for vessel markers angioinvasion
Because of angioinvasion
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immunostaining for the cell cycle-dependent marker 
Ki67 (MIB1) antigen, which is expressed in the nucleus. 
As an alternative to Ki67, the proliferation cell nuclear 
antigen can be used  [15] . To determine the Ki67 (MIB1) 
labeling index, 100 tumor cells have to be assessed in a 
hot-spot area. In case the Ki67 positivity is unevenly dis-
tributed, several tumor areas should be evaluated. The 
Ki67 labeling index then serves as the basis for grading 
the tumors as G1 ( ! 2%), G2 ( 1 2–20%) or G3 ( 1 20%) ( ta-
ble 2 )  [1, 2] . G1 and G2 GEP-NETs are well differentiated 
and display diffuse and intense expression of the two 
neuroendocrine markers, chromogranin A and synapto-
physin. G3 indicates a poorly differentiated neuroendo-
crine carcinoma that shows staining for synaptophysin 
but not (or only little) for chromogranin A.
 Immunostaining for hormones that are specific to cer-
tain cell types in the intestine and the pancreas and are 
known to also occur in tumors is optional for the diag-
nosis of GEP-NETs. One reason for immunostaining is to 
verify the production of a hormone causing a syndrome 
at the tumor cell level  [3] . Another reason is to identify a 
special tumor type, for instance a duodenal gangliocytic 
paraganglioma, by identifying hormones characterizing 
the neoplasm. The third reason is to identify hormones 
in a liver or lymph node biopsy specimen that shows a 
metastasis of a well-differentiated NET. The expression 
of certain hormones such as serotonin, gastrin, glucagon 
and pancreatic polypeptide may provide clues to the site 
of the primary tumor. Serotonin positivity suggests, first 
of all, a primary in the ileum; gastrin suggests a primary 
in the duodenum or the pancreas, and glucagon/pancre-
atic polypeptide suggests a primary in the pancreas.
 Optional in the standardized protocol is also the ap-
plication of antibodies for the immunostaining of soma-
tostatin receptors, in particular of somatostatin receptor 
2 (SSTR2). GEP-NETs that are positive for SSTR2 are, in 
the majority of cases, also depicted by an octreotide scan 
 [16] . In some case, immunostaining for vessel markers to 
verify tumor angioinvasion may be helpful.
 If the diagnosis is to be made on a resection specimen, 
the microscopic procedure is preceded by careful macro-
scopic examination ( table 3 ). This results in data on the 
precise localization of the tumor, its size, its composition 
(presence of necrosis or cystic changes), its relationship 
to anatomic structures, resection margins and adjacent 
organs, and the presence of lymph node and other metas-
tases. All of this information is needed in order to stage 
the tumor according to the recently proposed TNM stag-
ing classifications  [1, 2] . The tissue must be adequately 
sampled to allow a precise microscopic assessment of the 
tumor tissue. Formalin is recommended for the fixation 
of the tissue. The removal of fresh tissue for special bio-
logical examinations is optional.
 The microscopic evaluation of the resected tumor fol-
lows the guidelines given above for tumor tissue in bi-
opsy specimens. In addition, information has to be pro-
vided on invasion of lymph and blood vessels, nerves and 
resection margins. Staining for hormones is optional ( ta-
ble 1 ).
 Problems 
 Gastrointestinal and pancreatic adenocarcinomas 
with mixed differentiation present a special challenge in 
the classification  [17] . In most of these neoplasms, the 
cells staining for synaptophysin and chromogranin A 
represent a minor component of the total tumor cell pop-
ulation. Regarding their prognosis and treatment, it has 
been found that they behave like the respective adeno-
carcinomas without endocrine cells. The mixed carcino-
mas should therefore be clearly distinguished from the 
pure GEP-NETs.
Table 2. Grading proposal for GEP-NETs from Rindi et al. [1]
Grade Mitotic count, 10 HPF1 Ki67 index, %2
G1 1 ≤5
G2 2–20 3–20
G3 >20 >20
1 HPF = high-power field = 2 cm2, at least 40 fields evaluated 
in areas at highest mitotic density.
2 MIB1 antibody; % of 2,000 cells in areas of highest nuclear 
labeling.
Table 3. Musts and options for the assessment of resected GEP-
NETs
Macroscopy
Must
Determination of the size of the specimen, appearance, re-
lationship to other organs and resection margins
Staining of critical resection margin; preparation of lymph 
nodes/metastases
Optional
Removal of fresh tissue
Microscopy, see biopsy specimen (table 1)
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 Prognostic Stratification 
 On the basis of the information and data obtained from 
the macroscopic and microscopic evaluation, i.e. TNM 
stage, grade and tumor type, a prognostic stratification of 
the tumors may be performed.  Table 4 represents a pro-
posal for stratifying GEP-NETs into three groups for pur-
poses of treatment: (1) tumors that are still localized, (2) 
tumors with lymph node metastases, and (3) tumors with 
lymph node and hematogenous metastases.
 Conclusions 
 The proposed standard procedure for the diagnosis of 
GEP-NETs is simple and easy to perform. Based on the 
WHO classifications  [14, 18] and recently published re-
views and guidelines  [1–3, 19, 20] , it allows for the correct 
recognition and prognostic stratification of an individu-
al GEP-NET, in order to assure its adequate treatment. It 
is hoped that this approach will prove helpful for the stan-
dardization of the diagnosis and treatment of GEP-
NETs.
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Erratum
In the paper by Klöppel et al. [Neuroendocrinology 2009;90:162–166], please replace 
table 2 with the table below as the Ki67 index value for Grade 1 was incorrect.
Table 2. Grading proposal for GEP-NETs from Rindi et al. [1]
Grade Mitotic count, 10 HPF1 Ki67 index, %2
G1 1 ≤2
G2 2–20 3–20
G3 >20 >20
1 HPF = high-power field = 2 mm2, at least 40 fields evaluated 
in areas at highest mitotic density.
2 MIB1 antibody; % of 2,000 cells in areas of highest nuclear 
labeling.
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